Welcome to our dedicated page for Candel Therapeutics SEC filings (Ticker: CADL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Candel Therapeutics, Inc. filings document a clinical-stage oncology company developing multimodal biological immunotherapies and reporting as a Nasdaq-listed issuer of common stock. Its proxy materials cover director elections, auditor ratification and annual-meeting voting matters, while Form 8-K reports furnish operating and financial results and research-and-development presentations.
Other filings disclose material agreements and capital-structure matters, including term-loan financing and facility lease amendments, along with clinical and regulatory disclosures tied to aglatimagene besadenovec and linoserpaturev. The filing record also reflects governance matters, shareholder voting mechanics and exhibit-based disclosures for key corporate actions.
Candel Therapeutics Chief Medical Officer William Garrett Nichols received a stock option award reported on a Form 4. On January 26, 2026, he was granted an option to buy 136,500 shares of Candel common stock at an exercise price of $6.01 per share.
The option vests in 48 equal monthly installments following January 26, 2026, contingent on his continued service. The option expires on January 26, 2036. After this grant, Nichols directly beneficially owns 136,500 derivative securities linked to Candel common stock.
Candel Therapeutics, Inc. reported a new stock option grant to its Chief Financial Officer, Charles Schoch. On January 26, 2026, he received options to purchase 232,000 shares of common stock at an exercise price of $6.01 per share.
These options vest over time. The underlying shares will vest and become exercisable in forty-eight equal monthly installments following January 26, 2026, and each installment depends on his continued service with the company on the relevant vesting date.
Candel Therapeutics, Inc. reported that its Chief Executive Officer and director, Paul Peter Tak, received a grant of stock options. On January 26, 2026, he was awarded an option to purchase 629,000 shares of common stock at an exercise price of $6.01 per share.
The option was granted directly to him and is subject to time-based vesting. The underlying shares vest in 48 equal monthly installments starting after January 26, 2026, contingent on his continued service with the company on each vesting date. Following this grant, he beneficially owned stock options for 629,000 shares.
Candel Therapeutics Chief Scientific Officer granted stock options
Candel Therapeutics’ Chief Scientific Officer, Francesca Barone, received a stock option to buy 232,000 shares of common stock at an exercise price of $6.01 per share. The option was granted on January 26, 2026 and expires on January 26, 2036.
The option vests over time rather than all at once. The shares underlying the option vest and become exercisable in 48 equal monthly installments following January 26, 2026, as long as Barone continues serving the company on each vesting date. After this grant, she beneficially owns 232,000 stock options directly.
BlackRock, Inc. has filed a Schedule 13G reporting beneficial ownership of 2,859,610 shares of Candel Therapeutics Inc. common stock, representing 5.2% of the class as of 12/31/2025. BlackRock reports sole voting power over 2,821,816 shares and sole dispositive power over all 2,859,610 shares, with no shared voting or dispositive power.
The filing notes that various underlying clients or investors have rights to dividends or sale proceeds, but no single person has more than five percent of Candel’s outstanding common shares. BlackRock certifies that the shares were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Candel Therapeutics.
Candel Therapeutics reported that it will host a virtual Research and Development Day on December 5, 2025, from 11:00 a.m. to 1:45 p.m. Eastern Time. The event will provide an extensive overview of the company’s viral immunotherapy approach and its oncology-focused pipeline.
The investor presentation used for the event is being furnished as Exhibit 99.1 and will also be available in the investor relations section of the company’s website. Candel states that this information is being furnished rather than filed and will not be treated as part of its other securities law filings.
Candel Therapeutics (CADL) reported a Q3 2025 net loss of $11.3 million, or $0.21 per share. Operating expenses rose to $13.2 million, driven by research and development of $8.5 million and general and administrative of $4.7 million. Other income benefited from a $1.1 million gain related to warrant liability remeasurement.
For the nine months ended September 30, 2025, net loss was $8.7 million, reflecting a $21.7 million non-cash gain from changes in warrant liability. Cash, cash equivalents and restricted cash totaled $87.2 million at quarter-end, with total assets of $93.6 million and stockholders’ equity of $80.1 million.
Subsequent to quarter-end, the company entered a new term loan facility of up to $130.0 million and drew $50.0 million on October 14, 2025 at a floating rate initially 10.25%, issued lender warrants, and repaid its SVB loan. A new $300.0 million shelf and a $50.0 million ATM were established in August 2025; no sales occurred under the 2025 ATM through November 5, 2025. As of November 5, 2025, shares outstanding were 54,898,303. Management believes existing resources will fund planned operations for at least 12 months.
Candel Therapeutics, Inc. filed a current report to disclose that it announced its financial results for the quarter ended September 30, 2025. The company issued a press release on November 13, 2025, and that release is included as Exhibit 99.1 to the report.
The disclosure is furnished rather than filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced. The report is signed on behalf of Candel Therapeutics by its President and Chief Executive Officer, Paul Peter Tak, M.D., Ph.D., FMedSci.
Candel Therapeutics entered a Loan and Security Agreement for up to $130.0 million in term debt with Trinity Capital and other lenders, securing the debt with a first‑priority lien on substantially all assets. The Company drew the $50.0 million first tranche at closing. Additional tranches of $20.0 million, $30.0 million, and $30.0 million are available upon meeting specified milestones or lender discretion.
The facility matures on October 1, 2030, carries a floating rate with a 9.75% floor (initial rate 10.25%), a 36‑month interest‑only period extendable by 12 months upon a commercial milestone, an Exit Fee of 4.25% on amounts drawn at maturity/early termination, and tiered prepayment premiums of 3%/2%/1%. If market cap is below $550 million, minimum pledged cash covenants apply at 67.5% of outstanding obligations from July 1, 2026 (until specified financings) and 75% from the earlier of October 1, 2027 or certain regulatory notices until approvals.
Lenders received warrants equal to 3.0% of each draw at a $5.89 exercise price; the first draw produced a warrant for 254,642 shares (10‑year term, cashless exercise). Existing warrants’ expiration was extended to September 30, 2027, and certain holders agreed to a 6‑month lock‑up and provided releases. Cash and equivalents were $87.2 million as of September 30, 2025. Interim CAN‑3110 data showed mOS of 11.8 months (arm A) and 12.0 months (arm B); additional arm C data are expected in Q4 2026.
Candel Therapeutics entered a Loan and Security Agreement for up to $130.0 million in term debt with Trinity Capital and other lenders, securing the debt with a first‑priority lien on substantially all assets. The Company drew the $50.0 million first tranche at closing. Additional tranches of $20.0 million, $30.0 million, and $30.0 million are available upon meeting specified milestones or lender discretion.
The facility matures on October 1, 2030, carries a floating rate with a 9.75% floor (initial rate 10.25%), a 36‑month interest‑only period extendable by 12 months upon a commercial milestone, an Exit Fee of 4.25% on amounts drawn at maturity/early termination, and tiered prepayment premiums of 3%/2%/1%. If market cap is below $550 million, minimum pledged cash covenants apply at 67.5% of outstanding obligations from July 1, 2026 (until specified financings) and 75% from the earlier of October 1, 2027 or certain regulatory notices until approvals.
Lenders received warrants equal to 3.0% of each draw at a $5.89 exercise price; the first draw produced a warrant for 254,642 shares (10‑year term, cashless exercise). Existing warrants’ expiration was extended to September 30, 2027, and certain holders agreed to a 6‑month lock‑up and provided releases. Cash and equivalents were $87.2 million as of September 30, 2025. Interim CAN‑3110 data showed mOS of 11.8 months (arm A) and 12.0 months (arm B); additional arm C data are expected in Q4 2026.
Candel Therapeutics, Inc. reported that on August 18, 2025 it signed a First Amendment to its lease with 117 Kendrick DE, LLC for approximately 15,197 rentable square feet at 117 Kendrick Street in Needham, Massachusetts. The amendment extends the lease term from August 31, 2026 to August 31, 2029. Starting September 1, 2026, annual base rent will be $607,880 and will rise by $15,197 each year during the extended term. The full lease amendment is filed as an exhibit and certain confidential portions have been redacted.